


GSK Q3 2017 results



Sales across all
3 businesses



New product sales

£1.7bn

+40% CER

Adjusted Group
operating margin

31.5%

Total EPS

24.8p

+46% CER

Adjusted EPS

32.5p


flat CER

Free cash flow
year to date

£1.6bn

Dividend

19p



Herpes zoster
virus of shingles

See **press release** on www.gsk.com for full details on Q3 2017
Please read the cautionary statement regarding **forward-looking statements**